Clinuvel Pharmaceuticals' drug SCENESSE® (afamelanotide) has received Health Canada's Notice of Compliance for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare metabolic disorder causing severe skin reactions to light. This approval allows Clinuvel to market SCENESSE® in Canada, joining previous approvals in Europe, the US, and Australia. SCENESSE® is the only approved systemic treatment for EPP, with a proven long-term safety profile backed by over 21,000 doses administered globally. The drug works by increasing melanin production to protect skin from light damage, offering significant benefit to patients with limited treatment options.
Lyft director Janey Whiteside sold 14,220 shares of the company's stock at a price of $17 per share. This transaction reflects a significant insider sale, which investors often watch as a signal of confidence or strategic portfolio management. The sa...
Rentokil Initial PLC has restructured its global operations into two divisions: North America and a consolidated international unit, aiming to enhance customer focus and operational excellence. The company appointed Matt Jochim as group chief transfo...
RBC Capital Markets maintains a 260p price target and outperform rating on IWG PLC, citing a 43% total return potential despite the company's first-half profit missing estimates. IWG's earnings before interest, tax, depreciation, and amortisation wer...
JP Morgan has upgraded Aviva to 'overweight' while downgrading Legal & General and M&G to 'underweight', citing a shift in relative value in the UK life insurance sector. Aviva has lagged peers but now shows better free cash flow yields and potential...
First Phosphate Corp. celebrated its recent listing on the Nasdaq Global Market by ringing the Opening Bell at the Nasdaq Market Site in New York on August 13, 2026. The company is building a vertically integrated mine-to-market lithium iron phosphat...
